FAIRFIELD, N.J., Feb. 6, 2012 /PRNewswire/ -- Aperture Health, Inc. (OTC APRE) announced that it has appointed and retained EFP Rotenberg, LLP, headquartered in Rochester, NY as its independent auditors, under the direction of Nicolas Bottini as its lead audit partner. EFP Rotenberg  is more than 150 employees strong, including 70 CPAs  servicing  more than 70 public companies and with a robust international practice, and significant experience in healthcare services.

James Hennig, R.Ph, Chief Executive Officer and Chairman of the Board of Directors commented, "We are very pleased with our appointment of EFP Rotenberg as our independent auditors furthering our goal to become a fully reporting public company in the future.  We are very excited that in addition to their strong reputation as an auditing firm,  their extensive experience in the healthcare arena will give them great insight into our business."

About Aperture Health, and Triad Therapeutics

Aperture Health through its wholly owned subsidiary Triad Therapeutics operates a fully JCAHO accredited home IV therapy company, achieving this "gold standard" status in 2007. The company has built a well respected reputation in its industry for its therapy expertise and commitment to care for its patient clients. The company services clients throughout the States of New Jersey, New York and Connecticut, providing opportunity for organic growth. Triad's full time marketing and sales personnel continuously represent the company in the core services areas, growing and maintaining the company's referral source base. Patient referrals are made from physicians, hospitals, insurance companies, veterinarians and hospice care providers that have established a professional rapport with Triad.

Safe Harbor

Certain statements in this news release are forward-looking, including (without limitation) growing revenues and earnings, expected results from current projects and attracting new business.  Undue reliance should not be placed on such forward-looking statements because the matters they describe are subject to known and unknown risks, uncertainties and other unpredictable factors, many of which are beyond the Company's control. The Company's actual results, performance and trends could differ materially from those indicated or implied by such statements as a result of various factors, including (without limitation) the continued strengthening of Triad's selling and marketing functions, continued customer satisfaction, contract renewal, new product development, continued availability of capable dedicated personnel, continued cost management, success and availability of acquisitions, availability of financing and other factors, as well as by factors applicable to most companies such as general economic, competitive and other business and civil conditions.  Information regarding certain of those and other risk factors and cautionary statements that could affect future results, performance or trends is discussed in the Company's OTC Disclosure Statement and unaudited management financials posted on www.pinksheets.com .  All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.  The information set forth herein speaks only as of the date hereof.

SOURCE Aperture Health, Inc.

Copyright 2012 PR Newswire

Elinx (CE) (USOTC:ELNX)
過去 株価チャート
から 11 2024 まで 12 2024 Elinx (CE)のチャートをもっと見るにはこちらをクリック
Elinx (CE) (USOTC:ELNX)
過去 株価チャート
から 12 2023 まで 12 2024 Elinx (CE)のチャートをもっと見るにはこちらをクリック